1354621-59-2

Basic information

• Product Name: (3S,4S)-1-benzyl-N,4-diMethylpiperidin-3-aMine
• Synonyms: (3S,4S)-1-Benzyl-N,4-dimethyl-3-piperidinamine
• CAS NO: 1354621-59-2
• Molecular Formula: C14H22N2
• Molecular Weight: 218.33788
• EINECS: -0
• Mol File: 1354621-59-2.mol
• Article Data: 30

Chemical Properties

• Boiling Point: 302.641 °C at 760 mmHg
• Flash Point: 107.42 °C
• Appearance: /
• Density: 1.001 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.26±0.40(Predicted)
• CAS DataBase Reference: (3S,4S)-1-benzyl-N,4-diMethylpiperidin-3-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: (3S,4S)-1-benzyl-N,4-diMethylpiperidin-3-aMine(1354621-59-2)
• EPA Substance Registry System: (3S,4S)-1-benzyl-N,4-diMethylpiperidin-3-aMine(1354621-59-2)

Safety Data

• Hazardous Substances Data: 1354621-59-2(Hazardous Substances Data)

Usage

General Description

(3S,4S)-1-benzyl-N,4-diMethylpiperidin-3-aMine is a chemical compound with the molecular formula C16H24N2. It is a piperidine derivative that contains a benzyl group and two methyl groups. (3S,4S)-1-benzyl-N,4-diMethylpiperidin-3-aMine is a chiral molecule with a specific stereochemistry, denoted by the (3S,4S) designation, indicating the configuration of its stereocenters. It can be used as a building block in the synthesis of various pharmaceuticals and organic compounds. The presence of the benzyl and methyl groups gives this compound unique properties and potential biological activities that make it valuable for research and development in the field of medicinal chemistry.

Upstream product

• 77303-35-6 4-methyl-2,6-dioxo-1,2,5,6-tetrahydro-pyridine-3-carbonitrile 
• 68085-43-8 2-cyano-3-methylglutarimide 
• 32018-96-5 1-benzyl-4-methyl-piperidin-3-one 
• 74-89-5 methylamine 
• 1615709-89-1 1-benzyl-4-methyl-3-(methylamino)pyridinium bromide 
• 3430-22-6 3-Bromo-4-methylpyridin 
• 77862-24-9 4-Methyl-3-(methylamino)pyridine 
• 72093-04-0 3-chloro-4-methylpyridine 
• 923036-28-6 (1-benzyl-4-methyl-1,2,5,6-tetrahydropyridin-3-yl)carbamic acid methyl ester 
• 923036-27-5 1-benzyl-3-methoxycarbonylamino-4-methyl-pyridinium bromide 
• 384338-20-9 (3R,4R)-1-benzyl-4-methylpiperidin-3-ol 
• 100-46-9 benzylamine 
• 1092578-35-2 tert-butyl (3R,4S)-1-benzyl-4-methylpiperidin-3-ylcarbamate 
• 1092578-34-1 tert-butyl (3R,4R)-1-benzyl-4-methylpiperidin-3-ylcarbamate 

Downstream Products

• 1228879-37-5 cis-N-benzyl-3-methoxycarbonylamino-4-methylpiperidine bis(hydrochloride) 
• 1092578-48-7 tofacitinib 
• 923036-25-3 N-(trans-1-benzyl-4-methylpiperidin-3-yl)-2-chloro-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 1259404-17-5 3-(trans-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile 
• 1616761-00-2 3-[(3R,4R)-3-({2-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl}(methyl)amino)-4-methylpiperidin-1-yl]-3-oxopropanenitrile 
• 920965-91-9 N⁴-[(3R,4R)-1-benzyl-4-methyl-3-piperidinyl]-N⁴-methyl-2,3,4-pyridinetriamine 
• 1259404-17-5 tasocitinib 
• 1640971-60-3 3-[(3R,4R)-3-[(6-aminopyrimidin-4-yl)(methyl)amino]-4-methylpiperidin-1-yl]-3-oxopropanenitrile 
• 1206824-89-6 tert-butyl N-methyl-N-[(3R,4R)-4-methylpiperidin-3-yl]carbamate 
• 1206824-89-6 tert-butyl methyl(4-methylpiperidin-3-yl)carbamate 
• 1206824-89-6 tert-butyl methyl(4-methylpiperidin-3-yl)carbamate 

Relevant articles and documents

Formal asymmetric synthesis of (+)-tofacitinib

Tofacitinib is an efficient and selective Janus kinase 3 (JAK3) inhibitor, and is used as an immunosuppressant drug for the treatment of rheumatoid arthritis and transplant patients. Herein we report a concise formal asymmetric synthesis of tofacitinib from homochiral 1,3-dioxolanone 10b, which was elaborated through a highly stereoselective Michael addition followed by solvent-free removal of the chiral auxiliary and ring cyclization to furnish chiral imide 8. The preparation of tofacitinib's precursor 16 could be obtained after reduction of 8 followed by sequential oxidation, reductive amination and SNAr reactions.

Synthesis method of tofacitinib citrate diastereomer impurities

The invention discloses a synthesis method of tofacitinib citrate diastereomer impurities, relates to the technical field of drug organic synthesis, and relates to 3 - amino -4 - methylpyridine as a starting material and a quaternary ammonium salt. Raw materials of the whole synthetic route are easily available, the reaction conditions are mild, the post-treatment separation and purification operation is simple and feasible, and the preparation method is good in repeatability.

Preparation methods of tofacitinib intermediate amine and dihydrochloride thereof

The invention discloses preparation methods of tofacitinib intermediate amine and dihydrochloride thereof. According to the preparation method of the tofacitinib intermediate amine, methyl acetoacetate and cyanoacetamide are taken as starting materials and subjected to condensation, olefinic bond reduction, cyano hydrolysis into amide, N benzylation and Hofmann degradation to prepare primary amine, monomethylation and chiral resolution of the primary amine are performed, and a carbonyl group is reduced with zinc borohydride, so a target product is obtained. The obtained (3R,4R)-1-benzyl-3-methylamino-4-methylpiperidine is subjected to salifying with hydrochloric acid to obtain the dihydrochloride. The methods have the advantages that the whole process avoids a high-pressure hydrogenation reaction under an acidic condition; all the reaction steps adopt conventional reaction reagents and solvents, so raw material sources are not limited, and cost is low; and the method avoids a lithium aluminum hydride reduction reagent with high risk, each step has high selectivity, the reaction product of each step can be easily refined, and the method has advantages in industrialization.

Preparation method and application of chiral amine B

The invention discloses a preparation method of chiral amine B. The preparation method comprises the following steps: (1) carrying out nucleophilic substitution reaction on N-tert-butoxycarbonyl-3-pyridine and halogenated benzyl to obtain an intermediate